Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
On March1, 2017, Keryx Biopharmaceuticals, Inc. (Keryx) issued a
press release announcing its results of operations for the
quarter and year ended December31, 2016. Keryx also announced
that on March1, 2017 at 8:00 a.m. ET, it will host an investor
conference call to discuss its fourth quarter and full year 2016
financial results and provide a business update. A copy of such
press release is being furnished as Exhibit 99.1 to this report
and is incorporated herein by reference. A copy of the investor
presentation to be used on the investor conference call is being
furnished as Exhibit 99.2 to this report and is incorporated
herein by reference.
The information set forth in Exhibits 99.1 and 99.2 shall not be
deemed to be filed for purposes of Section18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liability of that section, and shall not be
incorporated by reference into any registration statement or
other document filed under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
| Item9.01. | Financial Statements And Exhibits. |
| (d) | Exhibits. |
The following exhibits are furnished herewith:
| 99.1 |
Press release issued by Keryx Biopharmaceuticals, Inc., dated March1, 2017. |
|
| 99.2 |
Investor presentation to be presented by Keryx Biopharmaceuticals, Inc. on March1, 2017. |
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) Recent Trading Information
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) closed its last trading session at with 1,898,358 shares trading hands.